Abstract

BackgroundBiochemical bone turnover markers are useful tools to assess bone remodeling. C-terminal telopeptide of type I collagen (ß-CTX) has been recommended as a reference marker for bone resorption in research studies.MethodsWe describe the results of a multicenter study for routine clinical laboratory assays for ß-CTX in serum and plasma. Four centers (Athens GR, Copenhagen DK, Liege BE and Sheffield UK) collected serum and plasma (EDTA) samples from 796 patients presenting to osteoporosis clinics. Specimens were analyzed in duplicate with each of the available routine clinical laboratory methods according to the manufacturers’ instructions. Passing-Bablok regressions, Bland–Altman plots, V-shape evaluation method, and Concordance correlation coefficient for ß-CTX values between serum and plasma specimens and between methods were used to determine the agreement between results. A generalized linear model was employed to identify possible variables that affected the relationship between the methods. Two pools of serum were finally prepared and sent to the four centers to be measured in 5-plicates on 5 consecutive days with the different methods.ResultsWe identified significant variations between methods and between centers although comparison results were generally more consistent in plasma compared to serum. We developed univariate linear regression equations to predict Roche Elecsys®, IDS-iSYS, or IDS ELISA ß-CTX results from any other assay and a multivariable model including the site of analysis, the age, and weight of the patient. The coefficients of determination (R2) increased from approximately 0.80 in the univariate model to approximately 0.90 in the multivariable one, with the site of analysis being the major contributing factor. Results observed on the pools also suggest that long-term storage could explain the difference observed with the different methods on serum.ConclusionOur results show large within- and between-assay variation for ß-CTX measurement, particularly in serum. Stability of the analyte could be one of the explanations. More studies should be undertaken to overcome this problem. Until harmonization is achieved, we recommend measuring ß-CTX by the same assay on EDTA plasma, especially for research purposes in large pharmacological trials where samples can be stored for long periods before they are assayed.

Highlights

  • Determination of C-terminal telopeptide (β-CTX) and N-terminal propeptide (PINP) of type I procollagen as reference markers of bone resorption and formation, respectively, Extended author information available on the last page of the article is recommended analytes since 2010 by the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Joint Working Group on Bone Marker Standards (WG-BMS) [1]

  • For PINP, we have recently shown that the two automated methods, IDS-iSYS (Boldon, UK), and Roche Elecsys® total P1NP assay run on cobas e family instruments (Mannheim, Germany) provided results that could be used interchangeably, allowing the application of similar reference ranges whatever the method, which is an important finding for the routine use of biomarkers outside the United States [4, 5]

  • We report the results of the comparison of β-CTX results generated by each of the available routine clinical assays on the samples of the patients enrolled in the multicenter study for which we have already reported the results for PINP [5]

Read more

Summary

Introduction

Determination of C-terminal telopeptide (β-CTX) and N-terminal propeptide (PINP) of type I procollagen as reference markers of bone resorption and formation, respectively, Extended author information available on the last page of the article is recommended analytes since 2010 by the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Joint Working Group on Bone Marker Standards (WG-BMS) [1]. As a result, these markers are recommended by IOF, the European Calcified Tissue Society (ECTS) and the Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) as useful tools for monitoring adherence of patients with osteoporosis to therapy with oral bisphosphonates [2, 3]. We recommend measuring ß-CTX by the same assay on EDTA plasma, especially for research purposes in large pharmacological trials where samples can be stored for long periods before they are assayed

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call